诺华公司Novartis（NVS）2024年年度报告「NYSE」（英文版）（263页）.pdf

1、Annual Report 2024 Annual Report 2024 IChairs letterIn our first full-year as a pure-play medicines company,Novartis delivered strong results,with double-digit growth in sales and net profit in 2024.The performance validates our strategy and gives us confidence that we are well prepared to grow by f

2、ocusing on our key thera-peutic areas and technologyplatforms.The strategic shift from a diversified life sciences com-pany to a focused medicines organization over the last decade has proven to be the right path forward.With the divestment of our non-core activities in animal health,vaccines and ge

3、nerics,among others,we were able to free up resources and strengthen our position in fast-growing and highly innovative medical fields such as xRNA,radioligand therapy and gene and cell therapy.Our recent breakthroughs in breast cancer and kidney and blood diseases demonstrate that our operational f

4、ocus strengthens our ability to deliver high-value medicines that alleviate societys greatest disease bur-dens.As we continue to accelerate our research and development efforts and strengthen our commercial capabilities,we expect to continue to grow profitably in the long-term and create sustainable

5、 shareholder value.Our efforts to more efficiently align our Research,Devel-opment and Commercial organizations advanced further.Besides strategic acquisitions to increase our techno-logical capacity and broaden our pipeline,we integrated artificial intelligence more deeply into our day-to-day opera

6、tions to more efficiently assess new molecules and accelerate drug development timelines.In view of continuing geopolitical and economic volatility,we are further strengthening our global production and distribution network to withstand potential supply chain disruptions and improve overall resilien